Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 9/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 3/20 | 0.31 |
| ▸ | CTSB | P07858 | 3/20 | 0.31 |
| ▸ | CTSH | P09668 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19576288 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2CTSKCASP1LMNAPOLB | |
| SCHEMBL22788848 | 0.89 | SMN1; SMN2 (0.38) | SMN1; SMN2CTSKCASP1LMNAPOLB | |
| SCHEMBL26560146 | 0.88 | SMN1; SMN2 (0.38) | SMN1; SMN2CTSKCASP1LMNAPOLB | |
| SCHEMBL20809975 | 0.85 | CTSK (0.38) | SMN1; SMN2CTSKCASP1LMNAPOLB | |
| SCHEMBL17346684 | 0.83 | DPP7 (0.40) | SMN1; SMN2CTSKCASP1CTSLCTSB | |
| SCHEMBL20375823 | 0.83 | DPP7 (0.40) | SMN1; SMN2CTSKCASP1CTSLCTSB | |
| SCHEMBL25561016 | 0.83 | CTSK (0.41) | SMN1; SMN2CTSKCTSLCTSBCTSH | |
| SCHEMBL19576301 | 0.83 | CTSK (0.41) | SMN1; SMN2CTSKCTSLCTSBCTSH | |
| SCHEMBL20998301 | 0.83 | CTSK (0.38) | SMN1; SMN2CTSKCASP1CTSLCTSB | |
| SCHEMBL17326111 | 0.83 | SMN1; SMN2 (0.37) | SMN1; SMN2CTSKCASP1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238433-A1 | ANTI-CEACAM5/6 ANTIGEN-BINDING MOLECULES AND METHODS OF TREATMENT THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-07-18 | — | — | US | disclosed |
| WO-2023098831-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | 嘉兴优博生物技术有限公司 | 2023-06-08 | — | — | WO | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| EP-4019507-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | Philochem AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3891138-B1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2022-01-12 | — | — | EP | disclosed |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-01-11 | — | — | US | disclosed |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2021-02-09 | — | — | US | disclosed |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2020-08-27 | — | — | US | disclosed |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-04-28 | — | — | US | disclosed |
| US-20190269788-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-09-05 | — | — | US | disclosed |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2019-06-11 | — | — | US | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | SMN1; SMN2 4595/4885CTSK 1720/4885CASP1 3089/4885 |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | IGF1R, IGFBP1, IGFBP5 | SMN1; SMN2 3883/4885CTSK 3396/4885CASP1 2616/4885 |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | SMN1; SMN2 4439/4885CTSK 1361/4885CASP1 1782/4885 |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | SMN1; SMN2 3883/4885CTSK 3396/4885CASP1 2616/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | SMN1; SMN2 4439/4885CTSK 1361/4885CASP1 1782/4885 |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DAD1, DDOST, KRTCAP2 | SMN1; SMN2 3829/4885CTSK 1806/4885CASP1 2747/4885 |
| US-20240238433-A1 | ANTI-CEACAM5/6 ANTIGEN-BINDING MOLECULES AND METHODS OF TREATMENT THEREOF | EPCAM, GP6, SELPLG | SMN1; SMN2 3584/4885CTSK 2603/4885CASP1 4813/4885 |
| US-20190269788-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | SMN1; SMN2 4595/4885CTSK 1720/4885CASP1 3089/4885 |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | DDOST, DAD1, KRTCAP2 | SMN1; SMN2 4543/4885CTSK 1436/4885CASP1 1824/4885 |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | KRTCAP2, DDOST, DAD1 | SMN1; SMN2 4595/4885CTSK 1720/4885CASP1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.